Diamonds and Dogs


Bristol-Myers Squibb (BMY) shocked Wall Street by announcing Friday that its new cancer drug Opdivo has failed a trial as a single therapy for newly diagnosed lung cancer patients. The stock is down 15%, dropping as much as 18% on the news. This was the first conspicuous miss for the drug since it launched in late 2014 and has already been approved for six different indications in melanoma, kidney cancer, lymphoma and later-stage lung cancer after acing clinical trials. Bristol-Myers also reported positive data for Opdivo in front-line lung cancer in combination with another cancer drug, Yervoy, back in June.


No fire in FireEye (FEYE). The security software firm beat estimates, but missed sales and guided full year earnings guidance below consensus. The new CEO announced a restructuring plan seeking to cut about $80 million in annual expenses or 9% of its controllable costs, laying off about 300 to 400 people. Not good news for Fireye.

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.